


UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/781,077	02/09/2001	James L. Holloway	00-18	7482
75	90 05/13/2002			
Susan E. Lingenfelter ZymoGenetics, Inc. 1201 Eastlake Avenue East			EXAMINER	
			SAOUD, CHRISTINE J	
Seattle, WA 98	3102		ART UNIT	PAPER NUMBER
			-1647	~
			DATE MAILED: 05/13/2002	2

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/781,077

Applicant(s)

.

HOLLOWAY et al.

Examiner

Christine Saoud

Art Unit **1647**



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
Period	for Reply	
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	T TO EXPIRE MONTH(S) FROM
af - If the be	ter SIX (6) MONTHS from the mailing date of this communical period for reply specified above is less than thirty (30) day be considered timely.	s, a reply within the statutory minimum of thirty (30) days will
co - Failu - Any	ommunication. re to reply within the set or extended period for reply will, b	period will apply and will expire SIX (6) MONTHS from the mailing date of this y statute, cause the application to become ABANDONED (35 U.S.C. § 133). e mailing date of this communication, even if timely filed, may reduce any
Status	· · · · · · · · · · · · · · · · · · ·	
1) 🗌	Responsive to communication(s) filed on	
2a) 🗌	This action is FINAL . 2b) 💢 This ac	tion is non-final.
3) 🗌	Since this application is in condition for allowance closed in accordance with the practice under $Ex\ partial$	except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposi	tion of Claims	
4) 💢	Claim(s) <u>1-30</u>	is/are pending in the application.
4	4a) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗆	Claim(s)	is/are allowed.
6) 🗌	Claim(s)	is/are rejected.
7) 🗌	Claim(s)	is/are objected to.
8) 💢	Claims <u>1-30</u>	are subject to restriction and/or election requirement.
Applica	ition Papers	
9) 🗆	The specification is objected to by the Examiner.	
10)	The drawing(s) filed on is/are	e objected to by the Examiner.
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved.
12)	The oath or declaration is objected to by the Exam	iner.
Priority	under 35 U.S.C. § 119	
13) 🗌	Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d).
a) 🗆	☐ All b)☐ Some* c)☐ None of:	
	1. \square Certified copies of the priority documents have	ve been received.
	2. \square Certified copies of the priority documents have	ve been received in Application No
	 Copies of the certified copies of the priority of application from the International Bure ee the attached detailed Office action for a list of the 	
14)	Acknowledgement is made of a claim for domestic	
A + + a = h		
Attachm 15) 🔲 N	ent(s) otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:

Application/Control Number: 09/781,007

Art Unit: 1647

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-10 and 30, drawn to polypeptides and compositions thereto, classified in class 530, subclass 300, for example.
 - II. Claims 11-28, drawn to polynucleotides, vectors, host cells, recombinant methods of protein production, classified in at least class 435, subclass 69.1, for example.
 - III. Claim 29, drawn to an antibody, classified in at least class 530, subclass 387.1, for example
- 2. The inventions are distinct, each from the other because of the following reasons: Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the polypeptides of Group I could be made by an entirely different process from using the polynucleotides, vectors, and host cells of Group II, such as by synthetic means. Additionally, Group II is independent and distinct from Group I because the DNAs, vectors, and host cells are materially different from and are therefore independent and distinct from the polypeptides of Group I. Neither are any of the polypeptides claimed in Group I needed for the invention of Group II.

Application/Control Number: 09/781,007

Page 3

Art Unit: 1647

3. Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptides of Group I could be used in an entirely different manner, such as in a therapeutic method rather than for the generation of the antibodies of Group III.

- 4. Inventions I and III are also unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are materially different, both structurally and functionally, from one another and are therefore independent and distinct.
- 5. Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are materially different, both structurally and functionally, from one another and are therefore independent and distinct. Furthermore, the polynucleotides of Group II are not required for the antibodies of Group III.
- 6. The inventions of each named pair can be shown to be distinct because they do not rely upon each other for their ultimate use and they require non-coextensive literature searches. The compounds are structurally different and the methods have different goals, method steps, and/or

Application/Control Number: 09/781,007

Art Unit: 1647

starting materials. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and the necessity for non-coextensive literature searches, restriction for examination purposes as indicated is proper.

Additional Restriction Requirement


7. The claims of Groups I-III are drawn to a multitude of nucleic acids, polypeptides, and antibodies thereto. These claims are not directed to a genus of compounds, but rather a multitude of distinct polynucleotides/polypeptides having distinct structures (as evidenced by at least claims 7 and 19). Each of the different polynucleotides/ polypeptides/ and antibodies thereto are independent and distinct because no common structural or functional properties are shared.

Accordingly, these claims are subject to restriction under 35 U.S.C. § 121.

Upon election of one of Groups I-III, Applicant is additionally required to elect a single polynucleotide/polypeptide (using items (a)-(p) of claim 7 or (a)-(q) of claim 19 as the distinct embodiments of the claims). This requirement is not to be construed as a requirement for an election of species, since each of the compounds recited in alternative form is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently



Art Unit: 1647

named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Species Election

- 9. If Group I is elected, this application contains claims directed to the following patentably distinct species of the claimed invention: affinity tags selected from the group consisting of polyhistidine tract, protein A, glutathione S transferase, Glu-Glu affinity tag, substance P, Flag peptide, streptavidin binding peptide, maltose-binding protein, and immunoglobulin domain.
- 10. If Group II is elected, this application contains claims directed to the following patentably distinct species of the claimed invention: prohormone convertase selected from the group consisting of prohormone convertase 1/3, prohormone convertase 2, prohormone convertase 4, PACE, PACE4, furin, and kex2.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 27 and 24 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations

Application/Control Number:

Art Unit: 1647

of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine Saoud, Ph.D., whose telephone number is (703) 305-7519. The examiner can normally be reached on Monday to Friday from 8AM to 3PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Official papers filed by fax should be directed to (703) 308-4556. If this number is out of service, please call the Group receptionist for an alternate number. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. Official papers should NOT be faxed to 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

CHRISTINE J. SAOUD

Chustin J. Saona